Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
Aileron Therapeutics’ (ALRN) Buy Rating Reiterated at HC Wainwright
11:18am, Monday, 29'th Jun 2020
Aileron Therapeutics (NASDAQ:ALRN)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday, AnalystRatings.com reports. They currently have a $2.00 price target on
William Blair Remains a Buy on Autolus Therapeutics (AUTL) - Markets
09:52am, Friday, 26'th Jun 2020
In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Autolus Therapeutics (AUTL – Research
Dynavax (DVAX) Gets a Buy Rating from William Blair - Markets
12:05pm, Monday, 22'nd Jun 2020
In a report issued on June 19, Matt Phipps from William Blair maintained a Buy rating on Dynavax (DVAX –
Aduro BioTech (ADRO) Gets a Hold Rating from William Blair - Markets
04:15pm, Friday, 12'th Jun 2020
William Blair analyst Matt Phipps maintained a Hold rating on Aduro BioTech (ADRO – Research Report) on June 9. The
William Blair Reaffirms Their Buy Rating on Aileron Therapeutics (ALRN) - Markets
04:15pm, Friday, 12'th Jun 2020
William Blair analyst Matt Phipps maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report) on June 9. The
Largest Insider Trades of the Week
03:42pm, Friday, 12'th Jun 2020
Applied Molecular makes the list Continue reading...
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
01:54pm, Wednesday, 10'th Jun 2020
Aileron Therapeutics (ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,0
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
01:15pm, Thursday, 04'th Jun 2020
In addition, Aileron has granted the underwriter a 30-day option to purchase up to 1,363,636 additional shares of common stock at the public offering price, less the underwriting discounts and commiss
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs June 3)
Arena Pharmaceuticals, Inc. (...
Aileron Therapeutics Announces Proposed Public Offering of Common Stock
08:01pm, Wednesday, 03'rd Jun 2020
Aileron Therapeutics (ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to purch
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
02:22pm, Tuesday, 02'nd Jun 2020
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) * Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) *
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 1)
Adaptimmune Therapeutics PLC...
5 Top Stocks Up 100%+ in May With More Room to Run
12:34pm, Monday, 01'st Jun 2020
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
In this trial, ALRN-6924 is being evaluated as an agent to protect patients against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation). Patients in the trial hav
